Rationale and Study Design of the Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D): A Non-Randomised, Open Label, Adaptive Dose Finding Trial

BMJ Open - United Kingdom
doi 10.1136/bmjopen-2014-005559
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ


Related search